DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

American Journal of Physiology-Endocrinology and Metabolism, published by the American Physiological Society, stands as a leading platform for disseminating high-quality research in the fields of endocrinology, diabetes, and metabolism, as well as general physiology. With an impressive impact factor placing it within the Q1 category across multiple relevant disciplines (Endocrinology, Diabetes and Metabolism; Physiology; and Medical Physiology), this journal reflects its authoritative position in the scientific community. Spanning from 1980 to 2024, the journal consistently publishes groundbreaking studies and significant findings that advance our understanding of hormonal regulation and metabolic processes. Although it does not currently offer open access, it provides valuable resources for researchers, professionals, and students alike, eager to stay at the forefront of advancements in physiological sciences. Addressed in Rockville, Maryland, its commitment to excellence and rigorous peer review ensures that every article contributes essential insights to the field.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

ENDOCRINE JOURNAL, published by the Japan Endocrine Society, is a pivotal resource for researchers and professionals in the field of endocrinology, diabetes, and metabolism. With a long history dating back to 1954, this journal encompasses a comprehensive range of topics including hormonal regulation, pathophysiology of endocrine diseases, and innovative therapeutic approaches. Despite its classification as open access, the journal remains a beacon of knowledge, with impressive rankings—Q2 in Endocrinology, Diabetes and Metabolism and Q3 in Endocrinology for 2023—ensuring it is a respected source in the academic community. It serves as a critical platform for the dissemination of cutting-edge research, encouraging collaboration and facilitating advancements in understanding complex endocrine disorders. By subscribing to this journal, researchers and students gain access to seminal studies, clinical insights, and a wealth of information that drives this vital field forward.

The International Journal of Endocrinology is a premier peer-reviewed journal, published by HINDAWI LTD, focusing on the rapidly evolving fields of endocrinology, diabetes, and metabolism. Since its establishment in 2009, the journal has embraced an Open Access model, ensuring that cutting-edge research is accessible to a global audience without barriers. With an impressive Scopus rank placing it within the top quartiles of related fields, it ranks #103 in Endocrinology, Diabetes and Metabolism, showcasing its significant contribution to the ongoing discourse in these areas. The journal's scope includes original research, reviews, and clinical studies that advance understanding and treatment strategies for endocrine disorders. By bridging the gap between research, clinical practice, and patient care, the International Journal of Endocrinology serves as an essential resource for researchers, practitioners, and students dedicated to the field of endocrinology. Addressed from its headquarters in the United States, this journal not only contributes to academic advancement but also fosters international collaboration in addressing key challenges in endocrinology.

Annals of Pediatric Endocrinology & Metabolism, published by the Korean Society of Pediatric Endocrinology, is a vital resource for researchers, healthcare professionals, and students in the fields of endocrinology, diabetes, and pediatric health. With its commitment to open access since 2012, the journal facilitates the dissemination of groundbreaking research on pediatric endocrine disorders and metabolic diseases, ensuring that vital knowledge is accessible to a global audience. The journal maintains a reputable standing with a 2023 Scopus rank of #92 in Pediatrics and a Q3 quartile in Endocrinology, highlighting its impact on the field. Originating from South Korea, the journal fosters a collaborative network of researchers and advocates best practices in pediatric care through interdisciplinary studies. The Annals not only enhances scientific understanding but also emphasizes practical applications aimed at improving child health outcomes, making it an essential publication for academics and practitioners alike.

The Journal of Obesity & Metabolic Syndrome, published by the Korean Society for the Study of Obesity, is a premier, open access journal that has been championing research in the realms of endocrinology, diabetes, and metabolism since its inception in 2012. With an ISSN of 2508-6235 and an E-ISSN of 2508-7576, this journal has quickly established itself as a leading publication, currently ranked in the Q1 category within its field and occupying the 46th position out of 244 in Scopus' Medicine category, with an impressive 81st percentile ranking. The journal serves as a vital platform for disseminating high-quality research and innovative findings related to obesity and metabolic disorders, fostering collaboration among researchers, healthcare professionals, and students dedicated to advancing knowledge and treatment strategies. For those interested in contributing or gaining access to cutting-edge research, the journal emphasizes its commitment to open access principles by providing unrestricted access to its content, thereby enhancing the visibility and impact of studies within the global scientific community.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.